Two Sigma Investments’s Theriva Biologics TOVX Stock Holding History

Two Sigma Investments’s Portfolio TOVX Stock Details TOVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.02K	Sell	15,441 -26,896	-64%	-$5.3K	﹤0.01%	4545
2025 Q4	$8.91K	Sell	42,337 -19,500	-32%	-$5.77K	﹤0.01%	4030
2025 Q3	$25.1K	Buy	+61,837	New	+$26.8K	﹤0.01%	3584
2024 Q4	–	Sell	-13,566	Closed	-$18.7K	–	3490
2024 Q3	$18.7K	Buy	+13,566	New	+$66.2K	﹤0.01%	3023
2022 Q3	–	Sell	-645	Closed	-$34K	–	2829
2022 Q2	$34K	Sell	645 -8	-1%	-$458	﹤0.01%	2371
2022 Q1	$47K	Buy	653 +317	+94%	+$21.6K	﹤0.01%	2495
2021 Q4	$23K	Sell	336 -516	-61%	-$48.7K	﹤0.01%	4171
2021 Q3	$98K	Buy	852 +765	+879%	+$95.2K	﹤0.01%	4086
2021 Q2	$13K	Buy	+87	New	+$12.5K	﹤0.01%	3960
2019 Q1	–	Sell	-43	Closed	-$6K	–	3474
2018 Q4	$6K	Buy	+43	New	+$10.2K	﹤0.01%	2901

Other funds holding TOVX

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Two Sigma Investments's TOVX Position: Q1 2026 in Review

Two Sigma Investments reduced its Theriva Biologics (TOVX) stake by 64% in Q1 2026, selling an estimated $5.3K and leaving 15,441 shares worth $3.02K. The position accounts for ﹤0.01% of the portfolio, ranked #4545.

Two Sigma Investments first reported a position in TOVX in Q4 2018 and has held it in 10 quarters since. The position peaked at $98K in Q3 2021. 22 funds tracked by Wall St. Rank hold TOVX as of Q1 2026.

Two Sigma Investments held 15,441 shares of Theriva Biologics worth $3.02K as of Q1 2026.
Two Sigma Investments sold 26,896 Theriva Biologics shares in Q1 2026, an estimated $5.3K.
Theriva Biologics made up ﹤0.01% of Two Sigma Investments's portfolio in Q1 2026, its #4545 holding.
Two Sigma Investments first reported a position in Theriva Biologics in Q4 2018 and has held it in 10 quarters since.
Two Sigma Investments's Theriva Biologics position peaked at $98K in Q3 2021.
22 funds tracked by Wall St. Rank held Theriva Biologics as of Q1 2026.

Based on Two Sigma Investments's 13F filing for Q1 2026, filed 15 May 2026.